Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Asha S. Multani Image

      Asha S. Multani, Ph.D.

      Department of Genetics, Division of Discovery Science

      About Dr. Asha S. Multani

      Dr. Asha S. Multani, Associate Professor in the Department of Genetics, and the Co-Director of the MD Anderson Cytogenetics and Cell Authentication Core. She received her Ph.D. from Gujarat University, India in Genetics during which she trained extensively in clinical Cytogenetics. She obtained her postdoctoral training in the Department of Cancer Biology at The University of Texas MD Anderson Cancer Center, joined the Department of Genetics in 2002, where she established the Molecular Cytogenetics Facility as an Institutional specialty resource. Dr. Multani has extensive expertise in the field of Human and Mammalian Cytogenetics, and specializes in the evaluation of genetic instability and complex chromosomal rearrangements in cancer cells, telomere dysfunction, characterization of embryonic stem cells, and authentication of cell lines. She is actively involved in developing cutting edge assays in the facility and also contributes to  education and training.

      Visit the Cytogenetics and Cell Authentication Core website

      Read More

      Present Title & Affiliation

      Primary Appointment

      Professor, Genetics, The University of Texas MD Anderson Cancer Center, Houston

      Director, Cytogenetics and Cell Authentication Core (CCAC), Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Professor, Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      1993Gujarat University, Ahmedabad, IN, Cell Biology, Ph.D

      Postgraduate Training

      1995-1997Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas
      1993-1995Fellowship, Gujarat University, Ahmedabad

      Experience & Service

      Faculty Academic Appointments

      Associate Professor, Genetics, The University of Texas MD Anderson Cancer Center, Houston, 2016 - 2025

      Assistant Professor, Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2016

      Instructor, Department of Molecular Genetics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2002 - 2006

      Research Associate, Department of Cancer Biology, UT M. D. Anderson Cancer Center, Houston, TX, 1997 - 2002

      Administrative Appointments/Responsibilities

      Director, Cytogenetics and Cell Authentication Core (CCAC), Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present

      Co-Director, Cytogenetics and Cell Authentication Core (CCAC), Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - 2022

      Co-Director, Molecular Cytogenetics Core Facility, Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2003 - 2019

      Extramural Institutional Committee Activities

      Member, Mid-Term Faculty Progress Review Committee/WonJae Lee, Ph.D, The University of Texas MD Anderson Cancer Center, 2024

      Member, Mid-Term Faculty Progress Review Committee/Song Yi Ko, Ph.D, The University of Texas MD Anderson Cancer Center, 2022

      Member, Mid-Term Faculty Progress Review Committee/Roberto Rangel, Ph.D, The University of Texas MD Anderson Cancer Center, 2022

      Member, Mid-Term Faculty Progress Review Committee/Manjunath Nimmakayalu, Ph.D, The University of Texas MD Anderson Cancer Center, 2022

      Member, Mid-Term Faculty Progress Review Committee/Rachel Mullen, Ph.D, The University of Texas MD Anderson Cancer Center, 2021

      Member, Admission Committee, Cytogenetics Technology Program, School of Health Professions, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Member, Mid-Term Faculty Progress Review Committee/Shaofang Wu, Ph.D, The University of Texas MD Anderson Cancer Center, 2020

      Chair, Cytogenetics and Cell Authentication Core (CCAC) Oversite Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, Mid-Term Faculty Progress Review Committee/Shavali Shaikh, Ph.D, The University of Texas MD Anderson Cancer Center, 2019

      Member, India Steering Committee for Global Academic Programs, The University of Texas MD Anderson Cancer Center, 2009 - 2011

      Chair, Molecular Cytogenetics Oversite Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2019

      Honors & Awards

      2000Best abstract award, 5TH World Congress on Advances in oncology and 3rd International Symposium on Molecular Medicine
      1993 - 1995Research Associateships, Government of India
      1985 - 1993Junior and Senior Research Fellowships, Government of India

      Professional Memberships

      American Association for Cancer Research

      2017 - Present

      American Society of Human Genetics

      2014 - Present

      Indian Society for Prenatal Diagnosis and Therapy

      1987 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2025. Cytogenetics and Cell Authentication Core. The University of Texas MD Anderson Cancer Center. Houston, Texas, US.
      2. 2025. Tissue Culture Techniques, A Comprehensive Review in Clinical Cytogenetics 2025. The University of Texas MD Anderson Cancer Center. Houston, Texas, US.
      3. 2024. Cytogenetics and Cell Authentication Core. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
      4. 2024. Tissue Culture Techniques, A Comprehensive Review in Clinical Cytogenetics 2024. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
      5. 2024. Cytogenetics and Cell Authentication Core. The University of Texas MD Anderson Cancer Center. Galveston, TX, US.
      6. 2023. The Cytogenetics and Cell Authentication Core Progress Report. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
      7. 2023. Tissue Culture Techniques, A Comprehensive Review in Clinical Cytogenetics 2023, US.
      8. 2023. Cell line Authentication. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
      9. 2022. Cytogenetics and Cell Authentication Core Progress Report. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
      10. 2018. Molecular Cytogenetics Facility, Significance of cytogenetics in biomedical research, US.
      11. 2016. Molecular Cytogenetics Facility. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
      12. 2016. Molecular Cytogenetics Facility. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
      13. 2015. Molecular Cytogenetics Facility. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
      14. 2014. Molecular Cytogenetics Facility. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
      15. 2014. Molecular Cytogenetics Facility. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
      16. 2014. Molecular Cytogenetics Facility. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
      17. 2012. Molecular Cytogenetics Facility. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
      18. 2011. Molecular Cytogenetics Facility. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
      19. 2011. Molecular Cytogenetics Facility. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
      20. 2011. Molecular Cytogenetics Core Facility. The University of Texas MD Anderson Cancer Center. Houston, Texas, US.

      Regional Presentations

      1. 2024. Cytogenetics and Cell Authentication Core. UT Austin and MD Anderson Collaborative Research Summit. Houston, Texas, US.
      2. 2022. Cytogenetics and Cell Authentication Core. UT Austin and MD Anderson Collaborative Research Summit. Austin, TX, US.

      National Presentations

      1. 2021. Advances and Application of Molecular Cytogenetic Techniques in Biomedical Research FaMe Physician Scientist Program, US.
      2. 2006. Generation of a mouse model of Li Fraumeni Syndrome. Cold Spring Harbor, NY, US.

      International Presentations

      1. 2022. Molecular Cytogenetics: its implications in Biomedical Research. Ahmedabad, India.
      2. 2022. Molecular Cytogenetics: its implications in Biomedical Research. Ahmedabad, India.
      3. 2021. Telomere Biology in Cancer. Ahmedabad, India.
      4. 2004. Essential role of limiting telomeres in the pathogenesis of Werner syndrome. Corfu, Greece.
      5. 2000. Telomeres: Target for Cancer therapy?. Crete, Greece.
      6. 1995. Differential cell-killing activity of Paclitaxel and its water-soluble derivatives. Halkidiki, Greece.
      Read More
      Less

      Grant & Contract Support

      Date: 2022 - 2027
      Title:Additional Programmatic Institutional Support
      Funding Source:Institutional Support
      Role:PI
      Date: 2014 - Present
      Title:Programmatic Institutional Support
      Funding Source:Institutional Support
      Role:PI
      Date: 2008 - 2013
      Title:Cancer Center Support Grant (CCSG)
      Funding Source:NIH/NCI
      Role:Co-Director of Molecular Cytogenetics Facility
      ID:NCI# CA016672
      Title:CCSG Funding
      Funding Source:CCSG
      Role:PI

      Selected Publications

      Peer-Reviewed Articles

      1. Lin, Y, Wang, J, Wang, K, Bai, S, Thennavan, A, Wei, R, Yan, Y, Li, J, Elgamal, H, Sei, E, Casasent, A, Rao, M, Tang, C, Multani, AS, Ma, J, Montalvan, J, Nagi, C, Winocour, SJ, Lim, B, Thompson, A, Navin, NE. Normal breast tissues harbour rare populations of aneuploid epithelial cells. Nature 636(8043):663-670, 2024. e-Pub 2024. PMID: 39567687.
      2. Li M, Lulla AR, Wang Y, Tsavachidis S, Wang F, Karakas C, Nguyen TDT, Bui TN, Pina MA, Chen MK, Mastoraki S, Multani AS, Fowlkes NW, Sahin A, Marshall CG, Hunt KK, Keyomarsi K. Low Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer. Cancer Res 84(22):3864-3880, 2024. e-Pub 2024. PMID: 39186665.
      3. Lee J, Kida K, Koh J, Liu H, Manyam GC, Gi YJ, Rampa DR, Multani AS, Wang J, Jayachandran G, Lee DW, Reuben JM, Sahin A, Huo L, Tripathy D, Im SA, Ueno NT. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer. J Exp Clin Cancer Res 43(1):236, 2024. e-Pub 2024. PMID: 39164784.
      4. Zhao M, Wang T, Gleber-Netto FO, Chen Z, McGrail DJ, Gomez JA, Ju W, Gadhikar MA, Ma W, Shen L, Wang Q, Tang X, Pathak S, Raso MG, Burks JK, Lin SY, Wang J, Multani AS, Pickering CR, Chen J, Myers JN, Zhou G. Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. Nat Commun 15(1):180, 2024. e-Pub 2024. PMID: 38167338.
      5. Ghayee, HK, Xu, Y, Hatch, H, Brockway, R, Multani, AS, Gu, T, Bollag, WB, Turcu, AF, Rainey, WE, Rege, J, Nanba, K, Bhagwandin, VJ, Nwariaku, F, Stastny, V, Gazdar, AF, Shay, JW, Auchus, RJ, Tevosian, SG. Development of Human Adrenocortical Adenoma (HAA1) Cell Line from Zona Reticularis. International journal of molecular sciences 24(1), 2023. e-Pub 2023. PMID: 36614027.
      6. Li M, Tsavachidis S, Wang F, Bui T, Nguyen TDT, Luo L, Multani AS, Bondy ML, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer. Oncogene 41(50):5331-5346, 2022. e-Pub 2022. PMID: 36344674.
      7. Lee, JJ, Kida, K, Liu, H, Gi, YJ, Manyam, GC, Wang, J, Multani, AS, Huo, L, Tripathy, D, Ueno, NT. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan, an anti-HER2 antibody-drug conjugate. European Journal of Cancer 174:S52-S53, 2022. e-Pub 2022.
      8. Song K, Minami JK, Huang A, Dehkordi SR, Lomeli SH, Luebeck J, Goodman MH, Moriceau G, Krijgsman O, Dharanipragada P, Ridgley T, Crosson WP, Salazar J, Pazol E, Karin G, Jayaraman R, Balanis NG, Alhani S, Sheu K, Ten Hoeve J, Palermo A, Motika SE, Senaratne TN, Paraiso KH, Hergenrother PJ, Rao PN, Multani AS, Peeper DS, Bafna V, Lo RS, Graeber TG. Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges. Cancer Discov 12(4):1046-1069, 2022. e-Pub 2022. PMID: 34930786.
      9. Tigano A, Khan R, Omer AD, Weisz D, Dudchenko O, Multani AS, Pathak S, Behringer RR, Aiden EL, Fisher H, MacManes MD. Chromosome size affects sequence divergence between species through the interplay of recombination and selection. Evolution 76(4):782-798, 2022. e-Pub 2022. PMID: 35271737.
      10. Wörmann SM, Zhang A, Thege FI, Cowan RW, Rupani DN, Wang R, Manning SL, Gates C, Wu W, Levin-Klein R, Rajapakshe KI, Yu M, Multani AS, Kang Y, Taniguchi CM, Schlacher K, Bellin MD, Katz MHG, Kim MP, Fleming JB, Gallinger S, Maddipati R, Harris RS, Notta F, Ross SR, Maitra A, Rhim AD. APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Nat Cancer 2(12):1338-1356, 2021. e-Pub 2021. PMID: 35121902.
      11. Bagheri-Yarmand R, Busaidy NL, McBeath E, Danysh BP, Evans KW, Moss TJ, Akcakanat A, Ng PKS, Knippler CM, Golden JA, Williams MD, Multani AS, Cabanillas ME, Shaw KR, Meric-Bernstam F, Shah MH, Ringel MD, Hofmann MC. RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient. Cancers (Basel) 13(19), 2021. e-Pub 2021. PMID: 34638434.
      12. Chakravarti D, Lee R, Multani AS, Santoni A, Keith Z, Hsu WH, Chang K, Reyes L, Rashid A, Wu CJ, Li J, Zhang J, Shim HS, Chandra K, Deng P, Spring DJ, Nielsen OH, Riis LB, Mayigegowda KK, Blutt SE, Zhang J, Younes M, DuPont A, Thirumurthi S, Vilar E, Estes MK, Colla S, Shroyer NF, DePinho RA. Telomere dysfunction instigates inflammation in inflammatory bowel disease. Proc Natl Acad Sci U S A 118(29), 2021. e-Pub 2021. PMID: 34253611.
      13. Hoencamp C, Dudchenko O, Elbatsh AMO, Brahmachari S, Raaijmakers JA, van Schaik T, Á SC, Contessoto VG, RGHP VH, van den Broek B, Mhaskar AN, Teunissen H, St Hilaire BG, Weisz D, Omer AD, Pham M, Colaric Z, Yang Z, Rao SSP, Mitra N, Lui C, Yao W, Khan R, Moroz LL, Kohn A, St Leger J, Mena A, Holcroft K, Gambetta MC, Lim F, Farley E, Stein N, Haddad A, Chauss D, Multani AS, Wang MC, Young ND, Hildebrandt E, Cheng HH, Knight CJ, Burnham TLU, Hovel KA, Beel AJ, Mattei PJ, Kornberg RD, Warren WC, Cary G, Gómez-Skarmeta JL, Hinman V, Lindblad-Toh K, Di Palma F, Maeshima K, Multani AS, Pathak S, Nel-Themaat L, Behringer RR, Kaur P, Medema RH, van Steensel B, de Wit E, Onuchic JN, Di Pierro M, Lieberman Aiden E, Rowland BD. 3D genomics across the tree of life reveals condensin II as a determinant of architecture type. Science 372(6545):984-989, 2021. e-Pub 2021. PMID: 34045355.
      14. Minussi DC, Nicholson MD, Ye H, Davis A, Wang K, Baker T, Tarabichi M, Sei E, Du H, Rabbani M, Peng C, Hu M, Bai S, Lin YW, Schalck A, Multani AS, Ma J, McDonald TO, Casasent A, Barrera A, Chen H, Lim B, Arun B, Meric-Bernstam F, Van Loo P, Michor F, Navin NE. Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature 592(7853):302-308, 2021. e-Pub 2021. PMID: 33762732.
      15. Chen B, Dragomir MP, Fabris L, Bayraktar R, Knutsen E, Liu X, Tang C, Li Y, Shimura T, Ivkovic TC, Cruz De Los Santos M, Anfossi S, Shimizu M, Shah MY, Ling H, Shen P, Multani AS, Pardini B, Burks JK, Katayama H, Reineke LC, Huo L, Syed M, Song S, Ferracin M, Oki E, Fromm B, Ivan C, Bhuvaneshwar K, Gusev Y, Mimori K, Menter D, Sen S, Matsuyama T, Uetake H, Vasilescu C, Kopetz S, Parker-Thornburg J, Taguchi A, Hanash SM, Girnita L, Slaby O, Goel A, Varani G, Gagea M, Li C, Ajani JA, Calin GA. The Long Noncoding RNA CCAT2 induces chromosomal instability through BOP1 - AURKB signaling. Gastroenterology 159(6):2146-2162, 2020. e-Pub 2020. PMID: 32805281.
      16. Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell 37(5):720-734.e13, 2020. e-Pub 2020. PMID: 32359397.
      17. Multani AS, Shaofang Wu, Feng Gao, Siyuan Zheng, Chen Zhang, Emmanuel Martinez-Ledesma, Ravesanker Ezhilarasan, Jie Ding, Xiaolong Li, Ningping Feng, Erik P Sulman, Roel G Verhaak, John F de Groot, Tim P Heffernan, W K Alfred Yung, Dimpy Koul. EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clin Cancer Res, 2019. PMID: 31852834.
      18. Wang R, Chu GC, Wang X, Wu JB, Hu P, Multani AS, Pathak S, Zhau HE, Chung LWK. Establishment and characterization of a prostate cancer cell line from a prostatectomy specimen for the study of cellular interaction. Int J Cancer 145(8):2249-2259, 2019. e-Pub 2019. PMID: 31020641.
      19. Veletic I, Manshouri T, Multani AS, Yin CC, Chen L, Verstovsek S, Estrov Z. Myelofibrosis osteoclasts are clonal and functionally impaired. Blood 23(21):2320-2324, 2019. e-Pub 2019. PMID: 30745304.
      20. Achuthan V, Perreira JM, Sowd GA, Puray-Chavez M, McDougall WM, Paulucci-Holthauzen A, Wu X, Fadel HJ, Poeschla EM, Multani AS, Hughes SH, Sarafianos SG, Brass AL, Engelman AN. Capsid-CPSF6 interaction licenses nuclear HIV-1 trafficking to sites of viral DNA integration. Cell Host and Microbe 24(3):392-404, 2018. e-Pub 2018. PMID: 30173955.
      21. deCarvalho AC, Kim H, Poisson LM, Winn ME, Mueller C, Cherba D, Koeman J, Seth S, Protopopov A, Felicella M, Zheng S, Multani A, Jiang Y, Zhang J, Nam DH, Petricoin EF, Chin L, Mikkelsen T, Verhaak RGW. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nat Genet 50(5):708-717, 2018. e-Pub 2018. PMID: 29686388.
      22. Multani AS, Wang M, Liang L, Lei, X, Meric-Bernstam F, Tripathy D, Wu Y, Chen H, Zhang H. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. Ann Diagn Pathol 35:69-76, 2018. e-Pub 2018. PMID: 29843069.
      23. Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28(4):432-447, 2018. e-Pub 2018. PMID: 29567676.
      24. Ong DST, Hu B, Ho YW, Sauvé CG, Bristow CA, Wang Q, Multani AS, Chen P, Nezi L, Jiang S, Gorman CE, Monasterio MM, Koul D, Marchesini M, Colla S, Jin EJ, Sulman EP, Spring DJ, Yung WA, Verhaak RGW, Chin L, Wang YA, DePinho RA. PAF promotes stemness and radioresistance of glioma stem cells. Proc Natl Acad Sci U S A 114(43):E9086-E9095, 2017. e-Pub 2017. PMID: 29073105.
      25. Sneige N, Hess KR, Multani AS, Gong Y, Ibrahim NK. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer 123(7):1115-1123, 2017. e-Pub 2017. PMID: 27893937.
      26. Graham NA, Minasyan A, Lomova A, Cass A, Balanis NG, Friedman M, Chan S, Zhao S, Delgado A, Go J, Beck L, Hurtz C, Ng C, Qiao R, Ten Hoeve J, Palaskas N, Wu H, Müschen M, Multani AS, Port E, Larson SM, Schultz N, Braas D, Christofk HR, Mellinghoff IK, Graeber TG. Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Mol Syst Biol 13(2):914, 2017. e-Pub 2017. PMID: 28202506.
      27. Sun Y, Ji P, Chen T, Zhou X, Yang D, Guo Y, Liu Y, Hu L, Xia D, Liu Y, Multani AS, Shmulevich I, Kucherlapati R, Kopetz S, Sood AK, Hamilton SR, Sun B, Zhang W. MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. J Pathol 241(1):67-79, 2017. e-Pub 2017. PMID: 27741356.
      28. Niu N, Zhang J, Zhang N, Mercado-Uribe I, Tao F, Han Z, Pathak S, Multani AS, Kuang J, Yao J, Bast RC, Sood AK, Hung MC, Liu J. Linking genomic reorganization to tumor initiation via the giant cell cycle. Oncogenesis 5(12):e281, 2016. e-Pub 2016. PMID: 27991913.
      29. Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, Knez L, Bozinovic K, Harris DM, Spaeth EL, Post SM, Multani AS, Rampal RK, Ahn J, Levine RL, Creighton CJ, Kantarjian HM, Estrov Z. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med 213(9):1723-40, 2016. e-Pub 2016. PMID: 27481130.
      30. Riley MF, You MJ, Multani AS, Lozano G. Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma. Oncogene 35(3):358-65, 2016. e-Pub 2016. PMID: 25915849.
      31. Gallardo M, Lee HJ, Zhang X, Bueso-Ramos C, Pageon LR, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J, Rapado I, Quintas-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM. hnRNP K is a novel haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies. Cancer Cell 28(4):486-499, 2015. e-Pub 2015. PMID: 26412324.
      32. Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJ, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell 27(5):644-57, 2015. e-Pub 2015. PMID: 25965571.
      33. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Ability to generate Patient-Derived Breast Cancer Xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes. PLoS One 10(9):10(9) e0136851, 2015. e-Pub 2015. PMID: 26325287.
      34. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, Multani A, Zhang H, Zhao R, Michor F, Meric-Bernstam F, Navin NE. Clonal evolution in breast cancer revealed by single nucleus genome sequence. Nature 512(7513):155-60, 2014. e-Pub 2014. PMID: 25079324.
      35. Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, Giri D, Cascone T, Kim JH, Ye Y, Multani AS, Chan CH, Erez B, Saigal B, Chung J, Lin HK, Wu X, Hung MC, Heymach JV, Lee MG. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest 123(12):5231-46, 2013. e-Pub 2013. PMID: 24200691.
      36. Malouf GG, Monzon FA, Couturier J, Molinié V, Escudier B, Camparo P, Su X, Yao H, Tamboli P, Lopez-Terrada D, Picken M, Garcia M, Multani AS, Pathak S, Wood CG, Tannir NM. Genomic Heterogeneity of Translocation Renal Cell Carcinoma. Clin Cancer Res 19(17):4673-84, 2013. e-Pub 2013. PMID: 23817689.
      37. Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S, Fodde R, Calin GA. CCAT2, a novel non-coding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res 23(9):1446-61, 2013. e-Pub 2013. PMID: 23796952.
      38. Yang G, Mercado-Uribe I, Multani AS, Sen S, IeM S, Wong KK, Gershenson DM, Liu J. RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis. Int J Cancer 133(2):275-85, 2013. e-Pub 2013. PMID: 23319376.
      39. Akbay EA, Peña CG, Ruder D, Michel JA, Nakada Y, Pathak S, Multani AS, Chang S, Castrillon DH. Cooperation between p53 and the telomere-protecting shelterin component Pot1a in endometrial carcinogenesis. Oncogene 32(17):2211-9, 2013. e-Pub 2013. PMID: 22689059.
      40. Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, Zhang L, Crossland D, Ang S, Torikai H, Rabinovich B, Lee DA, Kebriaei P, Hackett P, Champlin RE, Cooper LJ. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 36(2):112-23, 2013. e-Pub 2013. PMID: 23377665.
      41. Chen X, Liu B, Li Q, Honorio S, Liu X, Liu C, Multani AS, Calhoun-Davis T, Tang DG. Dissociated Primary Human Prostate Cancer Cells Coinjected with the Immortalized Hs5 Bone Marrow Stromal Cells Generate Undifferentiated Tumors in NOD/SCID-γ Mice. PLoS One 8(2):e56902, 2013. e-Pub 2013. PMID: 23451107.
      42. Ramirez E, Singh RR, Kunkalla K, Liu Y, Qu C, Cain C, Multani AS, Lennon PA, Jackacky J, Ho M, Dawud S, Gu J, Yang S, Hu PC, Vega F. Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma. Leuk Res 36(10):1267-73, 2012. e-Pub 2012. PMID: 22809693.
      43. Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, Galons H, Joseph B, Meijer L, Hunt KK, Keyomarsi K. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res Treat 132(2):575-88, 2012. e-Pub 2012. PMID: 21695458.
      44. Singh MM, Howard A, Irwin ME, Gao Y, Lu X, Multani A, Chandra J. Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia. PLoS One 7(12):e51611, 2012. e-Pub 2012. PMID: 23284724.
      45. Deriano L, Chaumeil J, Coussens M, Multani A, Chou Y, Alekseyenko AV, Chang S, Skok JA, Roth DB. The RAG2 C-terminus suppresses genomic instability and lymphomagenesis. Nature 471(7336):119-23, 2011. e-Pub 2011. PMID: 21368836.
      46. Multani AS, Chang S. Cytogenetic analysis of telomere dysfunction. Methods Mol Biol 735:139-43, 2011. e-Pub 2011. PMID: 21461818.
      47. Rai R, Zheng H, He H, Luo Y, Multani A, Carpenter PB, Chang S. The function of classical and alternative non-homologous end-joining pathways in the fusion of dysfunctional telomeres. EMBO J 29(15):2598-610, 2010. e-Pub 2010. PMID: 20588252.
      48. Thalmann GN, Rhee H, Sikes RA, Pathak S, Multani A, Zhau HE, Marshall FF, Chung LW. Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP cells. Eur Urol 58(1):162-71, 2010. e-Pub 2010. PMID: 19747763.
      49. Vega F, Davuluri Y, Cho-Vega JH, Singh RR, Ma S, Wang RY, Multani AS, Drakos E, Pham LV, Lee YC, Shen L, Ambrus J, Medeiros LJ, Ford RJ. Side population of a murine mantle cell lymphoma model contains tumour-initiating cells responsible for lymphoma maintenance and dissemination. J Cell Mol Med 14(6B):1532-45, 2010. e-Pub 2010. PMID: 19656242.
      50. Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S, Multani AS, Mercado-Uribe I, Liu J. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res 16(12):3171-81, 2010. e-Pub 2010. PMID: 20423983.
      51. Liang Y, Gao H, Lin SY, Peng G, Huang X, Zhang P, Goss JA, Brunicardi FC, Multani AS, Chang S, Li K. BRIT1/MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice. PLoS Genet 6(1):e1000826, 2010. e-Pub 2010. PMID: 20107607.
      52. Atanassov BS, Evrard YA, Multani AS, Zhang Z, Tora L, Devys D, Chang S, Dent SY. Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. Mol Cell 35(3):352-364, 2009. e-Pub 2009. PMID: 19683498.
      53. Jaiswal AS, Aneja R, Connors SK, Joshi HC, Multani AS, Pathak S, Narayan S. 9-bromonoscapine-induced mitotic arrest of cigarette smoke condensate-transformed breast epithelial cells. J Cell Biochem 106(6):1146-1156, 2009. e-Pub 2009. PMID: 19229861.
      54. He H, Wang Y, Guo X, Ramchandani S, Ma J, Shen MF, Garcia DA, Deng Y, Multani AS, You MJ, Chang S. Pot1b deletion and telomerase haploinsufficiency in mice initiate an ATR-dependent DNA damage response and elicit phenotypes resembling dyskeratosis congenita. Mol Cell Biol 29(1):229-40, 2009. e-Pub 2009. PMID: 18936156.
      55. Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS, Lim S, Coleman IM, Wu LC, Figg WD, Dahut WL, Nelson P, Lee JK, Amin MB, Lyles R, Johnstone PA, Marshall FF, Chung LW. Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res 68(23):9996-10003, 2008. e-Pub 2008. PMID: 19047182.
      56. Bhatia B, Jiang M, Suraneni M, Patrawala L, Badeaux M, Schneider-Broussard R, Multani AS, Jeter CR, Calhoun-Davis T, Hu L, Hu J, Tsavachidis S, Zhang W, Chang S, Hayward SW, Tang DG. Critical and distinct roles of p16 and telomerase in regulating the proliferative lifespan of normal human prostate epithelial progenitor cells. J Biol Chem 283(41):27957-72, 2008. e-Pub 2008. PMID: 18662989.
      57. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 118(8):2697-2710, 2008. e-Pub 2008. PMID: 18618013.
      58. Singh B, Cook KR, Vincent L, Hall CS, Berry JA, Multani AS, Lucci A. Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J Surg Res 147(2):240-246, 2008. e-Pub 2008. PMID: 18498876.
      59. Bhatia B, Multani AS, Patrawala L, Chen X, Calhoun-Davis T, Zhou J, Schroeder L, Schneider-Broussard R, Shen J, Pathak S, Chang S, Tang DG. Evidence that senescent human prostate epithelial cells enhance tumorigenicity : cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT. Int J Cancer 122(7):1483-1495, 2008. e-Pub 2008. PMID: 18059027.
      60. Guardavaccaro D, Frescas D, Dorrello NV, Peschiaroli A, Multani AS, Cardozo T, Lasorella A, Iavarone A, Chang S, Hernando E, Pagano M. Control of chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature 452(7185):365-369, 2008. e-Pub 2008. PMID: 18354482.
      61. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67(15):7212-7222, 2007. e-Pub 2007. PMID: 17671189.
      62. Singh B, Vincent L, Berry JA, Multani AS, Lucci A. Cyclooxygenase-2 expression induces genomic instability in MCF 10A breast epithelial cells. J Surg Res 140(2):220-226, 2007. e-Pub 2007. PMID: 17418864.
      63. Ford RJ, Shen L, Lin-Lee YC, Pham LV, Multani A, Zhou HJ, Tamayo AT, Zhang C, Hawthorn L, Cowell JK, Ambrus JL. Development of a murine model for blastoid variant mantle-cell lymphoma. Blood 109(11):4899-4906, 2007. e-Pub 2007. PMID: 17311992.
      64. Kupferman ME, Patel V, Sriuranpong V, Amornphimoltham P, Jasser SA, Mandal M, Zhou G, Wang J, Coombes K, Multani A, Pathak S, Silvio Gutkind J, Myers JN. Molecular analysis of anoikis resistance in oral cavity squamous cell carcinoma. Oral Oncol 43(5):440-54, 2007. e-Pub 2007. PMID: 16978912.
      65. Cosme-Blanco W, Shen MF, Lazar AJ, Pathak S, Lozano G, Multani AS, Chang S. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep 8(5):497-503, 2007. e-Pub 2007. PMID: 17396137.
      66. Chandel D, Multani AS. A unique case of Down syndrome with inherited maternal robertsonian translocation (21;21) and paternal inversion 9qh. J of cell and Tissue Res 7:1009-1011, 2007. e-Pub 2007.
      67. He H, Multani AS, Cosme-Blanco W, Tahara H, Ma J, Pathak S, Deng Y, Chang S. POT1b protects telomeres from end-to-end chromosomal fusions and aberrant homologous recombination. EMBO J 25(21):5180-90, 2006. e-Pub 2006. PMID: 17053789.
      68. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, Chung LW, Zhau HE. Prostate Cancer metastasis: Role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 66(15):1664-1673, 2006. e-Pub 2006. PMID: 16902972.
      69. Qutob SS, Multani AS, Pathak S, McNamee JP, Bellier PV, Liu QY, Ng CE. Fractionated X-radiation treatment can elicit an inducible-like radioprotective response that is not dependent on the intrinsic cellular X- radiation resistance/sensitivity. Radiat Res 166(4):590-599, 2006. e-Pub 2006. PMID: 17007548.
      70. Rai R, Dai H, Multani AS, Li K, Chin K, Gray J, Lahad JP, Liang J, Mills GB, Meric-Bernstam F, Lin SY. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell 10(2):145-57, 2006. e-Pub 2006. PMID: 16872911.
      71. Wu L, Multani AS, He H, Cosme-Blanco W, Deng Y, Deng JM, Bachilo O, Pathak S, Tahara H, Bailey SM, Deng Y, Behringer RR, Chang S. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell 126(1):49-62, 2006. e-Pub 2006. PMID: 16839876.
      72. Pathak S, Multani AS. Aneuploidy, stem cells and cancer. EXS(96):49-64, 2006. e-Pub 2006. PMID: 16383014.
      73. Laud PR, Multani AS, Bailey SM, Wu L, Ma J, Kingsley C, Lebel M, Pathak S, DePinho RA, Chang S. Elevated telomere-telomere recombination in WRN-deficient, telomere dysfunctional cells promotes escape from senescence and engagement of the ALT pathway. Genes Dev 19(21):2560-70, 2005. e-Pub 2005. PMID: 16264192.
      74. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7(5):469-83, 2005. e-Pub 2005. PMID: 15894267.
      75. Chang S, Multani AS, Cabrera NG, Naylor ML, Laud P, Lombard D, Pathak S, Guarente L, DePinho RA. Essential role of limiting telomeres in the pathogenesis of Werner syndrome. Nat Genet 36(8):877-82, 2004. e-Pub 2004. PMID: 15235603.
      76. Chen JS, Konopleva M, Andreeff M, Multani AS, Pathak S, Mehta K. Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis. J Cell Physiol 200(2):223-34, 2004. e-Pub 2004. PMID: 15174092.
      77. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64(9):3198-208, 2004. e-Pub 2004. PMID: 15126360.
      78. Qutob SS, Multani AS, Pathak S, Feng Y, Kendal WS, Ng CE. Comparison of the X-radiation, drug and ultraviolet-radiation responses of clones isolated from a human colorectal tumor cell line. Radiat Res 161(3):326-34, 2004. e-Pub 2004. PMID: 14982481.
      79. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK, Multani A, Chang S, Lozano G. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 36(1):63-8, 2004. e-Pub 2004. PMID: 14702042.
      80. Jaiswal AS, Multani AS, Pathak S, Narayan S. N-methyl-N'-nitro-N-nitrosoguanidine-induced senescence-like growth arrest in colon cancer cells is associated with loss of adenomatous polyposis coli protein, microtubule organization, and telomeric DNA. Mol Cancer 3:3, 2004. e-Pub 2004. PMID: 14728717.
      81. Sohn SH, Multani AS, Pathak S, Cho EJ, Ha HB. Chromosomal localization and distribution of the telomeric DNA in cattle and pigs. Anim. Sci. & Technol Kor(46):547 - 554, 2004. e-Pub 2004.
      82. Pathak S, Multani AS, Narayan S, Furlong CL, Hsu TC. Germline telomere length dynamics and mutagen sensitivity studies in a family with acute reactions to sun exposure: Involvement of three generations. Cancer Genomics & Proteomics 1:199 - 208, 2004. e-Pub 2004.
      83. Pathak S, Multani AS, Banerji P, Banerji P. Ruta 6 selectively induces cell death in brain cancer cells but proliferation in normal peripheral blood lymphocytes: A novel treatment for human brain cancer. Int J Oncol 23(4):975-82, 2003. e-Pub 2003. PMID: 12963976.
      84. Strickland FM, Pathak S, Multani AS, Pelley RP, Donawho CK. Molecular characterization of new melanoma cell lines from C3H mice induced by ethanol plus ultraviolet radiation. Cancer Res 63(13):3503-10, 2003. e-Pub 2003. PMID: 12839934.
      85. Chinni SR, Alhasan SA, Multani AS, Pathak S, Sarkar FH. Pleotropic effects of genistein on MCF-7 breast cancer cells. Int J Mol Med 12(1):29-34, 2003. e-Pub 2003. PMID: 12792805.
      86. Zhang X, Multani AS, Zhou JH, Shay JW, McConkey D, Dong L, Kim CS, Rosser CJ, Pathak S, Benedict WF. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. Cancer Res 63(4):760-5, 2003. e-Pub 2003. PMID: 12591722.
      87. Sohn SH, Multani AS, Gugnani PK, Pathak S. Telomere erosion-induced mitotic catastrophe in continuously grown chinese hamster don cells. Exp Cell Res 279(2):271-6, 2002. e-Pub 2002. PMID: 12243752.
      88. Multani AS, Weber KL, Pathak, S, Price JE. Characterization of a renal cell carcinoma cell line derived from a human bone metastasis and establishment of an experimental nude mouse model. J Urol 168(2):774-9, 2002. PMID: 12131367.
      89. Long DJ, Gaikwad A, Multani A, Pathak S, Montgomery CA, Gonzalez FJ, Jaiswal AK. Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res 62(11):3030-6, 2002. e-Pub 2002. PMID: 12036909.
      90. Devarajan E, Chen J, Multani AS, Pathak S, Sahin AA, Mehta K. Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. Int J Oncol 20(5):913-20, 2002. e-Pub 2002. PMID: 11956583.
      91. Shou J, Ali-Osman F, Multani AS, Pathak S, Fedi P, Srivenugopal KS. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene 21(6):878-89, 2002. e-Pub 2002. PMID: 11840333.
      92. Sohn SH, Ryu EK, Lee CY, Han JY, Multani AS, Pathak S. Rapid sex identification of chicken by fluorescence in situ hybridization using a W chromosome-specific DNA probe. Asian Australasian J of Animal Sciences 15(11):1531 -1535, 2002. e-Pub 2002.
      93. Srivenugopal KS, Shou J, Multani AS, Pathak S, Fedi P, Ali-Osman F. Human Dkk-1, a p53-inducible gene, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene 21:878 - 889, 2002. e-Pub 2002.
      94. Denison SR, Multani AS, Pathak S, Greenbaum IF. Fragility in the 14q21q translocation region. Genetics and Molecular Biology 25(3):271 - 276, 2002. e-Pub 2002.
      95. Multani AS, Y-J Z, Dworak RA, Furlong, CL, Pathak S. Telomere dynamics, mitotic catastrophe and causation of cancer: A study of human syndromes representing premature aging. Anti-Aging Medicine JAAM 5(2):271 - 281, 2002. e-Pub 2002.
      96. Multani AS, Worth LL, Jeha S, Chan KW, Pathak S. Human bone marrow transplant rejection is associated with telomere cleavage. Int J Mol Med 8(6):607-10, 2001. e-Pub 2001. PMID: 11712073.
      97. Fishman P, Bar-Yehuda S, Barer F, Madi L, Multani AS, Pathak S. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 269(2):230-6, 2001. e-Pub 2001. PMID: 11570815.
      98. Narayan S, Jaiswal AS, Multani AS, Pathak S. DNA damage-induced cell cycle checkpoints involve both p53-dependent and -independent pathways: role of telomere repeat binding factor 2. Br J Cancer 85(6):898-901, 2001. e-Pub 2001. PMID: 11556843.
      99. Multani AS, Ozen M, Furlong CL, Zhao YJ, Hsu TC, Pathak S. Heterochromatin and interstitial telomeric DNA homology. Chromosoma 110(3):214-20, 2001. e-Pub 2001. PMID: 11513296.
      100. Rhee HW, Zhau HE, Pathak S, Multani AS, Pennanen S, Visakorpi T, Chung LW. Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel. In Vitro Cell Dev Biol Anim 37(3):127-40, 2001. e-Pub 2001. PMID: 11370803.
      101. Pathak S, Multani AS, McConkey DJ, Imam AS, Amoss MS. Spontaneous regression of cutaneous melanoma in sinclair swine is associated with defective telomerase activity and extensive telomere erosion. Int J Oncol 17(6):1219-24, 2000. e-Pub 2000. PMID: 11078808.
      102. Pathak S, Multani AS, Narayan S, Kumar V, Newman RA. Anvirzel, an extract of Nerium oleander, induces cell death in human but not murine cancer cells. Anticancer Drugs 11(6):455-63, 2000. e-Pub 2000. PMID: 11001386.
      103. Multani AS, Ozen M, Narayan S, Kumar V, Chandra J, McConkey DJ, Newman RA, Pathak S. Caspase-dependent apoptosis induced by telomere cleavage and TRF2 loss. Neoplasia 2(4):339-45, 2000. e-Pub 2000. PMID: 11005568.
      104. Fishman P, Bar-Yehuda S, Ohana G, Pathak S, Wasserman L, Barer F, Multani AS. Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor. Eur J Cancer 36(11):1452-8, 2000. e-Pub 2000. PMID: 10899660.
      105. Pathak S, Nemeth MA, Multani AS. Author reply. Cancer 86(5):899-900, 1999. e-Pub 1999. PMID: 10463992.
      106. Multani AS, Ozen M, Sen S, Mandal AK, Price JE, Fan D, Radinsky R, Ali-Osman F, Von Eschenbach AC, Fidler IJ, Pathak S. Amplification of telomeric DNA directly correlates with metastatic potential of human and murine cancers of various histological origin. Int J Oncol 15(3):423-9, 1999. e-Pub 1999. PMID: 10427120.
      107. Multani AS, Pathak S. Conventional cytogenetics alone is not sufficient for identifying interspecies cell line contamination. Anticancer Res 19(3A):1753-4, 1999. e-Pub 1999. PMID: 10470110.
      108. Multani AS, Ozen M, Agrawal A, Hopwood VL, von Eschenbach AC, Pathak S. Amplification of the Y chromosome in three murine tumor cell lines transformed in vivo by different human prostate cancers. In Vitro Cell Dev Biol Anim 35(4):236-9, 1999. e-Pub 1999. PMID: 10478804.
      109. Pai SA, Cheung MC, Romsdahl MM, Multani AS, Pathak S. Can genetic instability be studied at the single chromosome level in cancer cells? Evidence from human melanoma cells. Cancer Genet Cytogenet 109(1):51-7, 1999. e-Pub 1999. PMID: 9973960.
      110. Multani AS, Li C, Ozen M, Imam AS, Wallace S, Pathak S. Cell-killing by paclitaxel in a metastatic murine melanoma cell line is mediated by extensive telomere erosion with no decrease in telomerase activity. Oncol Rep 6(1):39-44, 1999. e-Pub 1999. PMID: 9864398.
      111. Multani AS, Chandra J, McConkey DJ, Sen S, Cabral TF, Pathak S. Cell death in paclitaxel-dependent chinese hamster ovary cells is initiated by the loss of telomeric DNA repeats. Oncol Res 11(10):455-60, 1999. e-Pub 1999. PMID: 10850886.
      112. Multani AS, Furlong C, Pathak S. Reduction of telomeric signals in murine melanoma and human breast cancer cell lines treated with 3'-azido-2'-3'-dideoxythymidine. Int J Oncol 13(5):923-5, 1998. e-Pub 1998. PMID: 9772280.
      113. Pathak S, Nemeth MA, Multani AS. Human tumor xenografts in nude mice are not always of human origin: a warning signal. Cancer 83(9):1891-3, 1998. e-Pub 1998. PMID: 9806646.
      114. Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet 106(2):105-9, 1998. e-Pub 1998. PMID: 9797773.
      115. Ozen M, Imam SA, Datar RH, Multani AS, Narayanan R, Chung LW, von Eschenbach AC, Pathak S. Telomeric DNA: marker for human prostate cancer development?. Prostate 36(4):264-71, 1998. e-Pub 1998. PMID: 9719027.
      116. Mukhopadhyay T, Multani AS, Roth JA, Pathak S. Reduced telomeric signals and increased telomeric associations in human lung cancer cell lines undergoing p53-mediated apoptosis. Oncogene 17(7):901-6, 1998. e-Pub 1998. PMID: 9780006.
      117. Büssing A, Multani AS, Pathak S, Pfüller U, Schietzel M. Induction of apoptosis by the N-acetyl-galactosamine-specific toxic lectin from Viscum album L. is associated with a decrease of nuclear p53 and Bcl-2 proteins and induction of telomeric associations. Cancer Lett 130(1-2):57-68, 1998. e-Pub 1998. PMID: 9751257.
      118. Pathak S, Multani AS, Ozen M, Richardson MA, Newman RA. Dolastatin-10 induces polyploidy, telomeric associations and apoptosis in a murine melanoma cell line. Oncol Rep 5(2):373-6, 1998. e-Pub 1998. PMID: 9468560.
      119. Pathak S, Dolhonde JA, Multani AS. Amplification of telomeric DNA and the extent of karyotypic evolution. Cytobios 93(374):141-6, 1998. e-Pub 1998. PMID: 9779588.
      120. Multani AS, Li C, Ozen M, Yadav M, Yu DF, Wallace S, Pathak S. Paclitaxel and water-soluble poly (L-glutamic acid)-paclitaxel, induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line. Anticancer Res 17(6D):4269-74, 1997. e-Pub 1997. PMID: 9494519.
      121. Augenlicht LH, Wadler S, Corner G, Richards C, Ryan L, Multani AS, Pathak S, Benson A, Haller D, Heerdt BG. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57(9):1769-75, 1997. e-Pub 1997. PMID: 9135021.
      122. Chinoy NJ, Multani AS, Chakravarty N. Effects of papaya seed benzene extract on sister chromatid changes, chromosomal aberrations and cell cycle proliferative index in human human lymphocytes. Medicinal and Aromatic Plant Sciences 19:403 - 405, 1997. e-Pub 1997.
      123. Multani AS, Shah VC, Singh D, Chakravarty N, Chinoy NJ, Pathak S. Deletion/Inversion in the X-chromosome and increased telomeric associations in a female with primary amenorrhoea. Brazilian J. Genetics 20(3):511 - 516, 1997. e-Pub 1997.
      124. Yu YE, Stoica G, Multani AS, Zhang W, Pathak S, Wong, PKY. Characterization of a transgene-induced mutant mouse line which showed thymus atrophy and demyelination. Mouse Genome 95:704 - 706, 1997. e-Pub 1997.
      125. Ozen M, Multani AS, Kuniyasu H, Chung LW, von Eschenbach AC, Pathak S. Specific histologic and cytogenetic evidence for in vivo malignant transformation of murine host cells by three human prostate cancer cell lines. Oncol Res 9(8):433-8, 1997. e-Pub 1997. PMID: 9436196.
      126. Pathak S, Nemeth MA, Multani AS, Thalmann GN, von Eschenbach AC, Chung LW. Can cancer cells transform normal host cells into malignant cells?. Br J Cancer 76(9):1134-8, 1997. e-Pub 1997. PMID: 9365160.
      127. Multani AS, Hopwood VL, Pathak S. A modified fluorescence in situ hybridization (FISH) technique. Anticancer Res 16(6B):3435-7, 1996. e-Pub 1996. PMID: 9042203.
      128. Yadav M, Hopwood VL, Multani AS, Mansfield PF, Takahashi Y, McIntyre BW, Udagawa T, Pathak S. Non-random primary and secondary chromosomal abnormalities in human gastric cancers. Anticancer Res 16(4A):1787-95, 1996. e-Pub 1996. PMID: 8712702.
      129. Multani AS, Sheth FJ, Shah VC, Chinoy NJ, Pathak S. Three siblings with Harlequin Ichthyosis in an Indian family. Early Hum Dev 45(3):229-33, 1996. e-Pub 1996. PMID: 8855396.
      130. Ozen M, Multani A, Chang S, Von Eschenbach A, Chung L, Pathak S. Establishment of an in vitro cell model system to study human prostate carcinogenesis. Int J Oncol 8(5):883 - 888, 1996. e-Pub 1996. PMID: 21544441.
      131. Multani AS, Radhakrishna U, Sheth FJ, Shah VC, Chinoy NJ, Pathak S. Maternal inheritance of a 10/15 translocation in a female with bad obstetric history. Brazilian J. Genetics 19(3):497 - 500, 1996. e-Pub 1996.
      132. Pathak, S, Multani AS, Amoss MS, Jr. Telomere, telomerase and malignant melanomas in human and domestic mammals. Archivos de Zootechnia 45:141 - 149, 1996. e-Pub 1996.
      133. Sheth FJ, Multani AS, Sheth JJ, Radhakrishna U, Shah VC, Chinoy NJ. Incomplete gonadal dysgenesis. Urol Int 56(1):57-60, 1996. e-Pub 1996. PMID: 8903559.
      134. Sheth FJ, Multani AS, Shah VC, Chinoy NJ. Fetal malformations caused by amnion rupture. Indian J Pediatr 62(3):369-72, 1995. e-Pub 1995. PMID: 10829893.
      135. Sheth FJ, Radhakrishna U, Multani AS, Shah VC, Chinoy NJ. Acrocentric chromosomes association in couples with repeated fetal loss. Indian J. Clinical Practice 6:66 - 70, 1995. e-Pub 1995.
      136. Shah VC, Chinoy NJ, Multani AS, Sheth FJ, Smart V. Human sex determination and male abnormalities. Proceedings of Zoological Society 47 No. 2(Calcutta):135 - 140, 1995. e-Pub 1995.
      137. Sheth FJ, Radhakrishna U, Multani AS, Shah VC, Chinoy NJ. A female with isodicentric X chromosome idic (Xq) associated with ovarian dysgenesis. Indian J Pediatr 61(2):189-92, 1994. e-Pub 1994. PMID: 7927618.
      138. Sheth FJ, Multani AS, Chinoy NJ. Sister chromatid exchanges: A study in fluorotic individuals of North Gujarat. Fluoride 4:215 - 219, 1994. e-Pub 1994.
      139. Radhakrishna U, Multani AS, Solanki JV, Shah VC, Chinoy NJ. Polydactyly: a study of a five generation Indian family. J Med Genet 30(4):296-9, 1993. e-Pub 1993. PMID: 8487274.
      140. Multani AS, Radhakrishna U, Sheth FJ, Shah VC, Chinoy NJ. Translocation t(22;22)(p11.1;q11.1) and NOR studies in a female with a history of repeated fetal loss. Ann Genet 35(2):105-9, 1992. e-Pub 1992. PMID: 1524406.
      141. Shah VC, Sheth FJ, Chinoy NJ, Murthy SK, Multani AS, Radhakrishna U, Shah GH, Banker GJ, Patel AJ. Human Sex Determination and Development. Everyman's Science(Dec 89-Jan 90):224 - 228, 1990. e-Pub 1990.
      142. Shah VC, Chinoy, NJ, Sheth FJ, Murthy SK, Multani AS, Shah GH, Banker GJ, Patel AJ. Cytogenetics of Human sex variants. Genetical Research(BARC, Bombay):228 - 230, 1990. e-Pub 1990.
      143. Sheth FJ, Shah VC, Chinoy NJ, Murthy SK, Multani AS, Highland HN, Radhakrishna U. Repeated fetal loss in referred cases: A study on 14 couples with spontaneous abortion. Ind. J. Obstet. Gynec 38(3):247 - 277, 1988. e-Pub 1988.

      Invited Articles

      1. Multani AS, Chang S. WRN at telomeres: implications for aging and cancer. J Cell Sci 120(Pt 5):713-721, 2007. e-Pub 2007. PMID: 17314245.

      Review Articles

      1. Pathak S, Multani AS, Furlong CL, Sohn SH. Telomere dynamics, aneuploidy, stem cells, and cancer (review). Int J Oncol 20(3):637-41, 2002. e-Pub 2002. PMID: 11836581.

      Other Articles

      1. Sheth FJ, Shah VC, Chinoy NJ, Murthy DSK, Multani, AS, Shah GH, Banker GJ, Patel AJ A 46, XY male with absent gonads. In: Proceedings of DAE symposium on Human Genetics. Proceedings of DAE symposium on Human Genetics:247-250, 1989.
      2. Multani AS, Shah VC, Chinoy NJ, Murthy D, Sheth FJ Clinical, Cytogenetic and endocrine studies in a 46, XX male: A case report. Proceedings of DAE symposium on Human Genetics:247-253, 1989.

      Book Chapters

      1. Amoss Jr MS, Fadok VA, Multani AS, Pathak S, Greene Jr JF, Measel Jr JW, Morgan Jr CD. Advances in swine in Biomedical Research. In: Advances in swine in Biomedical Research. Plenum Press, 319 - 330, 2000.
      2. Multani AS, Ma J, Pathak S. Cytogenetic Characterization of commonly used Mammalian species in Bio-medical Research. In: The AGT Cytogenetics and Cytogenomics Manual, 5th Edition. Wiley Pub.

      Letters to the Editor

      1. Mehta K, Devarajan E, Chen J, Multani A, Pathak S. Multidrug-resistant MCF-7 cells: an identity crisis?. J Natl Cancer Inst 94: 1652-4; author reply 1654, 2002.
      2. Multani AS, Kacker RK, Pathak S. Are Robertsonian translocations rare in cancers?. Cancer Genet Cytogenet 93: 179-80, 1997.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top